Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Eytan M. Stein,Eytan M. Stein,Courtney D. DiNardo,Amir T. Fathi,Daniel A. Pollyea,Richard Stone,Jessica K. Altman,Gail J. Roboz,Gail J. Roboz,Manish R. Patel,Robert H. Collins,Ian W. Flinn,Mikkael A. Sekeres,Anthony S. Stein,Hagop M. Kantarjian,Ross L. Levine,Paresh Vyas,Kyle J. MacBeth,Alessandra Tosolini,Jason VanOostendorp,Qiang Xu,Ira Gupta,Thomas Lila,Alberto Risueño,Katharine E. Yen,Bin Wu,Eyal C. Attar,Martin S. Tallman,Martin S. Tallman,Stéphane de Botton,Stéphane de Botton +30 more
Reads0
Chats0
TLDR
Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed and clearance of mutant-IDH2 clones was also associated with achievement of CR.About:
This article is published in Blood.The article was published on 2019-02-14 and is currently open access. It has received 244 citations till now. The article focuses on the topics: Enasidenib & Survival rate.read more
Citations
More filters
Journal ArticleDOI
Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel.
Hartmut Döhner,Andrew H. Wei,Frederick R. Appelbaum,Charles Craddock,Courtney D. DiNardo,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Lucy A. Godley,Robert P. Hasserjian,Richard A. Larson,Ross Levine,Yasushi Miyazaki,Dietger Niederwieser,Gert J. Ossenkoppele,Christoph Röllig,Jorge Sierra,Eytan M. Stein,Martin S. Tallman,Hwei-Fang Tien,Jianxiang Wang,Agnieszka Wierzbowska,Bob Löwenberg +22 more
TL;DR: This update includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations for acute myeloid leukemia in adults, which are widely recognized among physicians and investigators.
Journal ArticleDOI
Targeting immunometabolism as an anti-inflammatory strategy
TL;DR: As accumulating evidence for roles of an intricate and elaborate network of metabolic processes, including lipid, amino acid and nucleotide metabolism provides key focal points for developing new therapies, glycolysis and the TCA cycle are turned to to provide examples of how metabolic intermediates and enzymes can provide potential novel therapeutic targets.
Journal ArticleDOI
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.
Nicholas J. Short,Marina Konopleva,Tapan M. Kadia,Gautam Borthakur,Farhad Ravandi,Courtney D. DiNardo,Naval Daver +6 more
TL;DR: The current and emerging therapeutic landscape of AML is discussed, highlighting novel classes of drugs and how the expanding knowledge of mechanisms of resistance are informing future therapies and providing new opportunities for effective combination strategies.
Journal ArticleDOI
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
Daniel A. Pollyea,Martin S. Tallman,Stéphane de Botton,Stéphane de Botton,Hagop M. Kantarjian,Robert H. Collins,Anthony S. Stein,Mark G. Frattini,Qiang Xu,Alessandra Tosolini,Wendy L. See,Kyle J. MacBeth,Samuel V. Agresta,Eyal C. Attar,Courtney D. DiNardo,Eytan M. Stein,Eytan M. Stein +16 more
TL;DR: Oral, outpatient targeted treatment with enasidenib may benefit older adults with newly diagnosed mutant-IDH2 AML who are not candidates for cytotoxic regimens.
Journal ArticleDOI
How I treat acute myeloid leukemia in the era of new drugs
TL;DR: This new addition to the How I Treat series will utilize three case presentations to discuss some of the new treatment challenges encountered in the management of AML, with the goal of providing practical guidance to aid the practising physician.
References
More filters
Journal ArticleDOI
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner,Elihu H. Estey,David Grimwade,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Richard A. Larson,Ross L. Levine,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Hwei-Fang Tien,Andrew H. Wei,Andrew H. Wei,Bob Löwenberg,Clara D. Bloomfield +22 more
TL;DR: An international panel to provide updated evidence- and expert opinion-based recommendations for diagnosis and management of acute myeloid leukemia in adults includes a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
Journal ArticleDOI
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang,David W. White,Stefan Gross,Bryson D. Bennett,Mark A. Bittinger,Edward M. Driggers,Valeria Fantin,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin Marks,Robert M. Prins,Patrick S. Ward,Katharine E. Yen,Linda M. Liau,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Matthew G. Vander Heiden,Shinsan M. Su +20 more
TL;DR: It is shown that cancer-associated IDH1 mutations result in a new ability of the enzyme to catalyse the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG), and that the excess 2HG which accumulates in vivo contributes to the formation and malignant progression of gliomas.
Journal ArticleDOI
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado,Michael S. Wolf,Marc Peeters,Eric Van Cutsem,Salvatore Siena,Daniel J. Freeman,Todd Juan,Robert Sikorski,Sid Suggs,Robert Radinsky,Scott D. Patterson,David D. Chang +11 more
TL;DR: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors, and KRAS status should be considered in selecting patients withmCRC as candidates for panitumuab mon Therapy.
Journal ArticleDOI
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil,Moritz Gerstung,Lars Bullinger,Verena I. Gaidzik,Peter Paschka,Nicola D. Roberts,Nicola E. Potter,Michael Heuser,Felicitas Thol,Niccolo Bolli,Gunes Gundem,Peter Van Loo,Inigo Martincorena,Peter Ganly,Laura Mudie,Stuart McLaren,Sarah O’Meara,Keiran Raine,David R. Jones,Jon W. Teague,Adam Butler,Mel Greaves,Arnold Ganser,Konstanze Döhner,Richard F. Schlenk,Hartmut Döhner,Peter J. Campbell +26 more
TL;DR: The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification.
Journal ArticleDOI
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson,John M. Bennett,Kenneth J. Kopecky,Thomas Büchner,Cheryl L. Willman,Elihu H. Estey,Charles A. Schiffer,Hartmut Doehner,Martin S. Tallman,T. Andrew Lister,Francesco Lo-Coco,Roel Willemze,Andrea Biondi,Wolfgang Hiddemann,Richard A. Larson,Bob Löwenberg,Miguel A. Sanz,David R. Head,Ryuzo Ohno,Clara D. Bloomfield +19 more
TL;DR: An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials as mentioned in this paper.
Related Papers (5)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein,Eytan M. Stein,Courtney D. DiNardo,Daniel A. Pollyea,Amir T. Fathi,Gail J. Roboz,Gail J. Roboz,Jessica K. Altman,Richard Stone,Daniel J. DeAngelo,Ross L. Levine,Ian W. Flinn,Hagop M. Kantarjian,Robert H. Collins,Manish R. Patel,Arthur E. Frankel,Anthony S. Stein,Mikkael A. Sekeres,Ronan T. Swords,Bruno C. Medeiros,Christophe Willekens,Christophe Willekens,Paresh Vyas,Alessandra Tosolini,Qiang Xu,Robert Knight,Katharine E. Yen,Sam Agresta,Stéphane de Botton,Stéphane de Botton,Martin S. Tallman,Martin S. Tallman +31 more
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner,Elihu H. Estey,David Grimwade,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Richard A. Larson,Ross L. Levine,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Hwei-Fang Tien,Andrew H. Wei,Andrew H. Wei,Bob Löwenberg,Clara D. Bloomfield +22 more
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil,Moritz Gerstung,Lars Bullinger,Verena I. Gaidzik,Peter Paschka,Nicola D. Roberts,Nicola E. Potter,Michael Heuser,Felicitas Thol,Niccolo Bolli,Gunes Gundem,Peter Van Loo,Inigo Martincorena,Peter Ganly,Laura Mudie,Stuart McLaren,Sarah O’Meara,Keiran Raine,David R. Jones,Jon W. Teague,Adam Butler,Mel Greaves,Arnold Ganser,Konstanze Döhner,Richard F. Schlenk,Hartmut Döhner,Peter J. Campbell +26 more
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard Stone,Sumithra J. Mandrekar,Ben L. Sanford,Kristina Laumann,Susan Geyer,Clara D. Bloomfield,Christian Thiede,Thomas W. Prior,Konstanze Döhner,Guido Marcucci,Francesco Lo-Coco,Rebecca B. Klisovic,Andrew H. Wei,Jorge Sierra,Miguel A. Sanz,Joseph Brandwein,Theo de Witte,Dietger Niederwieser,Frederick R. Appelbaum,Bruno C. Medeiros,Martin S. Tallman,Jürgen Krauter,Richard F. Schlenk,Arnold Ganser,Hubert Serve,Gerhard Ehninger,Sergio Amadori,Richard A. Larson,Hartmut Döhner +28 more